While reduced SIRT6 expression was observed in colon, liver, pancreatic, and ovarian cancers, where it functioned as a tumor suppressor, elevated SIRT6 expression was demonstrated in prostate cancer, acute myeloid leukemia, multiple myeloma, and osteosarcoma [14–21]. This evidence concerns the gene SIRT6 and Familial prostate cancer.